감염증 진단 시장 : 전략적 인사이트 및 예측(2026-2035년)

The Infectious Disease Diagnostics Market is expected to grow at a CAGR of 6.7% from a market value of USD 26.1 billion in 2026 to USD 46.9 billion in 2035.

The infectious disease diagnostics market is undergoing significant transformation driven by the paradigm shift toward rapid molecular testing, decentralized diagnostics, and integrated laboratory ecosystems. The market's evolution is characterized by the growing recognition that early pathogen identification with resistance profiling is essential for antimicrobial stewardship, infection control, and public health surveillance. The convergence of multiplex molecular diagnostics, next-generation sequencing, artificial intelligence, and laboratory automation is enabling faster, more comprehensive, and increasingly accessible infectious disease testing. Healthcare systems are prioritizing scalable diagnostic platforms capable of supporting both routine clinical testing and emergency outbreak response. The increasing burden of antimicrobial resistance is transforming diagnostic demand because clinicians require earlier organism identification together with resistance profiling before selecting targeted therapies. National preparedness initiatives continue to influence procurement priorities because governments recognize diagnostic infrastructure as an essential component of pandemic readiness. The market is witnessing significant investment in syndromic testing panels, point-of-care molecular diagnostics, genomic surveillance networks, and digital reporting systems, positioning infectious disease diagnostics as a critical component of modern healthcare delivery and public health infrastructure.

Market Drivers

• Increasing antimicrobial resistance represents the primary driver for the infectious disease diagnostics market. Antimicrobial resistance creates clinical uncertainty because empirical treatment frequently delays optimal therapy while increasing inappropriate antibiotic exposure. Healthcare providers are increasingly adopting molecular diagnostics that identify pathogens together with resistance-associated genetic markers during early patient management. Conventional microbiology continues to provide definitive confirmation, yet its longer turnaround time limits immediate treatment optimization. Diagnostic manufacturers are expanding rapid PCR panels, automated microbiology systems, and resistance detection assays that support antimicrobial stewardship programs, resulting in sustained growth in infectious disease diagnostic utilization. Expanding genomic surveillance is further accelerating market growth through adoption of next-generation sequencing. Pathogen surveillance depends upon genomic characterization because emerging variants influence disease transmission, vaccine effectiveness, and therapeutic selection. National surveillance programs are expanding sequencing capacity across reference laboratories to strengthen outbreak monitoring and public health preparedness. Laboratory infrastructure increasingly requires bioinformatics integration alongside sequencing technologies to manage larger genomic datasets. Diagnostic companies are responding by developing automated sequencing workflows and standardized analysis software that simplify routine implementation. Decentralized testing is accelerating point-of-care diagnostic adoption across healthcare settings. Healthcare delivery increasingly emphasizes earlier diagnosis because delayed testing contributes to disease transmission and prolonged hospitalization. Point-of-care molecular diagnostics are expanding into emergency departments, outpatient clinics, pharmacies, and community healthcare settings where rapid clinical decisions improve patient management. Healthcare providers continue requiring laboratory-quality analytical performance despite decentralized deployment. Manufacturers are developing compact automated systems that minimize operator complexity while maintaining diagnostic accuracy. Laboratory automation is improving operational efficiency and workflow standardization. Clinical laboratories process increasing testing volumes while facing workforce shortages and operational cost pressures. Automation is reducing manual sample handling, improving workflow consistency, and supporting standardized quality management across diagnostic laboratories. High-throughput molecular platforms increasingly integrate sample preparation, amplification, detection, and reporting within unified workflows.

Market Restraints

• High capital investment requirements for advanced molecular analyzers limit adoption among smaller healthcare facilities despite increasing clinical demand. The substantial upfront costs for instrumentation create barriers for resource-constrained settings. Reimbursement variability across healthcare systems reduces financial incentives for laboratories to implement newer high-complexity molecular diagnostic technologies. Inconsistent coverage policies limit patient access and create uncertainty for diagnostic providers. Regulatory validation requirements for multiplex molecular assays increase development timelines, clinical evidence generation, and commercialization costs. The rigorous approval processes create challenges for smaller diagnostic companies. Shortages of specialized laboratory professionals and molecular diagnostics expertise constrain efficient utilization of advanced platforms, limiting scalability in many healthcare settings.

Technology and Segment Insights

• The technology landscape is characterized by the growing importance of multiplex molecular diagnostics and integrated testing workflows. PCR remains the reference molecular technology because it provides high analytical sensitivity, specificity, and relatively rapid turnaround across a broad spectrum of pathogens. Clinical laboratories are expanding PCR utilization beyond single-pathogen detection toward multiplex respiratory, gastrointestinal, bloodstream, and sexually transmitted infection panels that improve diagnostic efficiency. Next-generation sequencing is gaining adoption for genomic surveillance, outbreak investigation, and antimicrobial resistance monitoring. Immunoassays continue supporting serological testing and rapid antigen detection. Clinical microbiology provides culture confirmation and susceptibility testing, yet longer processing times increase dependence on rapid molecular methods for initial clinical decisions. The segment analysis reveals that reagents and kits represent the largest recurring revenue component because every diagnostic workflow depends on consumables regardless of the installed instrument base. Healthcare providers are increasing testing frequency for respiratory infections, bloodstream infections, healthcare-associated infections, and sexually transmitted diseases, creating sustained demand for assay-specific consumables. Viral infections account for a substantial proportion of diagnostic demand because early pathogen identification directly influences antiviral therapy, infection control, and public health surveillance. Bacterial infections, including tuberculosis, hospital-acquired infections, and sexually transmitted bacterial infections, generate significant demand for rapid resistance detection. Fungal and parasitic infections represent important niche segments. Hospitals and clinics represent key end-user segments, with diagnostic laboratories playing a central role in specialized testing. Point-of-care testing is expanding across decentralized healthcare settings. The integration of AI is becoming increasingly important because diagnostic platforms generate complex molecular and genomic datasets requiring efficient interpretation. AI is assisting laboratories by improving workflow prioritization, quality assurance, and result interpretation across high-volume testing environments.

Competitive and Strategic Outlook

• The competitive landscape features established molecular diagnostics and life science companies alongside specialized infectious disease and point-of-care providers. F. Hoffmann-La Roche is a global leader in molecular diagnostics with the cobas portfolio, combining high-throughput automation with extensive infectious disease assay coverage and a strategy focused on integrated laboratory ecosystems and digital connectivity. Abbott offers infectious disease diagnostics across molecular, immunoassay, and rapid testing platforms through its Alinity and ID NOW portfolios, emphasizing decentralized testing and workflow automation. Danaher, through Cepheid and Beckman Coulter, provides rapid PCR, microbiology, and laboratory automation solutions, continuing to expand syndromic molecular diagnostics and antimicrobial resistance testing. Illumina is a leading provider of NGS platforms supporting infectious disease surveillance and pathogen genomics, with a strategy centered on scalable sequencing workflows and bioinformatics integration. DiaSorin develops molecular and immunodiagnostic solutions through its LIAISON platforms, continuing to expand assay menus and laboratory automation capabilities. bioMerieux specializes in clinical microbiology, syndromic molecular diagnostics, and antimicrobial susceptibility testing, supporting antimicrobial stewardship through rapid pathogen identification. QIAGEN provides sample preparation technologies, PCR assays, and syndromic testing through the QIAstat-Dx platform. BD offers automated microbiology systems, molecular diagnostics, and specimen collection solutions. Hologic delivers high-throughput molecular diagnostics through its Panther platform, particularly in sexually transmitted and viral infections. Companies are pursuing product portfolio expansion through innovation in multiplex syndromic panels, rapid point-of-care molecular tests, and AI-enabled interpretation software. Strategic collaborations between diagnostic manufacturers, healthcare providers, and public health agencies are increasing, driven by the need for antimicrobial stewardship and surveillance. Recent key developments include Seegene launching the industry's first Global Million Clinical Study evaluating 1 million real patient test records to validate a syndromic PCR testing strategy. Karius collaborated with Mayo Clinic Laboratories to make metagenomic infectious disease diagnostic tests available through streamlined sample submission. Bruker launched MyGenius PRO, a fully automated PCR-based molecular diagnostics system delivering up to 144 results in 8 hours with high-throughput walkaway automation. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

• The infectious disease diagnostics market is positioned for sustained growth driven by the convergence of antimicrobial resistance, genomic surveillance, decentralized testing, and laboratory automation. The transition from standalone laboratory testing toward integrated diagnostic ecosystems represents a fundamental shift in infectious disease management. While challenges related to high capital costs, reimbursement variability, and regulatory complexity persist, strategic investments in technology, automation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with infectious disease diagnostics evolving into a critical component of modern healthcare delivery, supporting rapid pathogen identification, antimicrobial stewardship, outbreak preparedness, and public health surveillance across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Global Infectious Disease Diagnostics Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Infectious Disease Diagnostics Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Infectious Disease Burden and Unmet Diagnostic Needs
• 3.8 Disease Prevalence Analysis
• 3.9 Diagnosed Patient Population Analysis
• 3.10 Testing Volume Analysis
• 3.11 Diagnostic Testing Pathway Analysis

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Diagnostic Technologies
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Diagnostic Pipeline Analysis
• 6.5 Artificial Intelligence Integration in Infectious Disease Diagnostics
• 6.6 Digital Health and Connected Diagnostics

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Global Infectious Disease Diagnostics Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Testing Methodology
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by End User

9. Global Infectious Disease Diagnostics Market Segment Analysis (2021-2035)

• 9.1 By Product
  • 9.1.1 Instruments & Analyzers
  • 9.1.2 Reagents & Kits
  • 9.1.3 Software & Services
• 9.2 By Technology
  • 9.2.1 Polymerase Chain Reaction (PCR)
  • 9.2.2 Isothermal Nucleic Acid Amplification
  • 9.2.3 Next-Generation Sequencing (NGS)
  • 9.2.4 Immunoassays
  • 9.2.5 Clinical Microbiology
  • 9.2.6 Other Molecular Diagnostic Technologies
• 9.3 By Test Type
  • 9.3.1 Laboratory-based Testing
  • 9.3.2 Point-of-Care Testing
• 9.4 By Disease Type
  • 9.4.1 Viral Infections
    • 9.4.1.1 COVID-19
    • 9.4.1.2 Influenza
    • 9.4.1.3 HIV/AIDS
    • 9.4.1.4 Hepatitis
    • 9.4.1.5 Human Papillomavirus (HPV)
    • 9.4.1.6 Others
  • 9.4.2 Bacterial Infections
    • 9.4.2.1 Tuberculosis (TB)
    • 9.4.2.2 Hospital-Acquired Infections (HAIs)
    • 9.4.2.3 Methicillin-resistant Staphylococcus aureus (MRSA)
    • 9.4.2.4 Sexually Transmitted Bacterial Infections
    • 9.4.2.5 Others
  • 9.4.3 Fungal Infections
  • 9.4.4 Parasitic Infections
• 9.5 By Sample Type
  • 9.5.1 Blood
  • 9.5.2 Serum
  • 9.5.3 Urine
  • 9.5.4 Stool
  • 9.5.5 Tissue Biopsy
  • 9.5.6 Other Sample Types
• 9.6 By End User
  • 9.6.1 Hospitals & Clinics
  • 9.6.2 Diagnostic Laboratories
  • 9.6.3 Academic & Research Institutes
  • 9.6.4 Other End Users

10. Global Infectious Disease Diagnostics Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Global Infectious Disease Diagnostics Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
  • 13.1.1 Company Overview
  • 13.1.2 Financials
  • 13.1.3 Product Portfolio
  • 13.1.4 Recent Developments
• 13.2 Abbott Laboratories
• 13.3 Danaher Corporation
• 13.4 Illumina Inc.
• 13.5 DiaSorin S.p.A.
• 13.6 bioMerieux SA
• 13.7 QIAGEN N.V.
• 13.8 Becton, Dickinson and Company
• 13.9 Hologic, Inc.
• 13.10 OraSure Technologies Inc.

14. Global Infectious Disease Diagnostics Market Commercial Forecast Analysis

• 14.1 Molecular Diagnostic Tests
• 14.2 Immunoassay-Based Diagnostic Tests
• 14.3 Clinical Microbiology Diagnostics
• 14.4 Rapid Antigen Diagnostic Tests
• 14.5 Point-of-Care Molecular Diagnostics
• 14.6 Multiplex Syndromic Panels
• 14.7 Next-Generation Sequencing-Based Infectious Disease Diagnostics

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends